Australia's Cyclopharm secures 11-site agreement in US

• Cyclopharm has finalised a system-wide agreement to install its medical imaging systems across 11 clinical locations in the United States.
• The company's stock responded positively to the announcement, finishing higher during local market trading.
• The deployment forms part of the ongoing commercial strategy to expand the enterprise footprint within major international healthcare networks.

Cyclopharm (ASX:CYC) executed an agreement with University Hospitals to install its Technegas system across 11 clinical locations.

This agreement avoids typical staged timelines by deploying the systems simultaneously across the network over the coming weeks.

The hospital group finished all site preparation work before signing to ensure immediate deployment without any operational delays.

The company stated that each site will generate recurring revenue from per-patient functional ventilation imaging procedures.

Following the announcement, the Cyclopharm share price was up at $0.64.

The initiative establishes the presence of the business in northern Ohio and supports its expanding United States footprint.

The partner healthcare network treats more than one million patients annually and maintains more than 32,000 workers.